LaunchCyte

LaunchCyte

Innovative solutions in healthcare, lighting, and display industries through unique university technologies.

  • Edit
Get premium to view all results
DateInvestorsAmountRound
N/A

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
N/A

$1.1m

Late VC
Total Funding000k
No items found
No investors found
Notes (0)
More about LaunchCyte
Made with AI
Edit

LaunchCyte LLC, founded in 2000, specializes in commercializing unique university technologies. The company operates a diverse portfolio of five companies—Celsense, Crystalplex, Immunetrics, Knopp Biosciences, and Reaction Biology—each offering specialized solutions in the healthcare, lighting, and display industries. LaunchCyte primarily serves clients in the healthcare sector, including research institutions, biotech firms, and medical professionals, as well as clients in the lighting and display markets. The company operates in the niche market of technology transfer, where it identifies promising university innovations and brings them to market. LaunchCyte's business model revolves around nurturing these technologies through early-stage development, securing intellectual property rights, and forming strategic partnerships to scale the businesses. Revenue is generated through product sales, licensing agreements, and research collaborations. The company leverages its strong network of industry experts and academic partners to drive growth and innovation.

Keywords: healthcare solutions, lighting technology, display technology, university innovations, biotech firms, research institutions, technology transfer, intellectual property, strategic partnerships, early-stage development.

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo

Investments by LaunchCyte

Edit
Immunetrics
ACQUISITION by Simulations Plus Jun 2023
Reaction Biology
ACQUISITION by Cobepa Mar 2022